Post-Market Safety Reassessment of Safflower and Aceglutamide Injection

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000031123

Enrollment

Unknown

Registered

2020-03-22

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All area

Interventions

case series:Safflower and Aceglutamide Injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All inpatients in the monitored hospitals who received Safflower And Aceglutamide Injectionby intravenous drip.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
AE/ADR;	—

Countries

China

Contacts

Public ContactSong Yanqing

yangqingyjk@163.com+86 15843079687

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026